Case reports: Subtrochanteric femoral stress fractures after prolonged alendronate therapy

Clinical Orthopaedics and Related Research

Volumn 468, Issue 7, 2010, Pages 1991-1996

  Cermak, Katerina ^a   Shumelinsky, Felix ^a   Alexiou, Jean ^a   Gebhart, Michael J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; BONE RADIOGRAPHY; CASE REPORT; DRUG WITHDRAWAL; FEMALE; FEMUR SUBTROCHANTERIC FRACTURE; FRACTURE HEALING; HUMAN; IMAGE ANALYSIS; INTRAMEDULLARY NAILING; LEG PAIN; MULTIPLE MYELOMA; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSYNTHESIS; PHYSICAL ACTIVITY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; STRESS FRACTURE; TREATMENT DURATION; BONE NAIL; FEMUR FRACTURE; INSTRUMENTATION; METHODOLOGY; MIDDLE AGED; RADIOGRAPHY; TREATMENT OUTCOME;

AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; BONE NAILS; FEMALE; FEMORAL FRACTURES; FRACTURE FIXATION, INTRAMEDULLARY; FRACTURES, STRESS; HUMANS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 77954002824     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1007/s11999-009-1192-0     Document Type: Article

References (29)

1. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009; 24:1095-1102.
2. Allen MR, Gineyts E, Leeming DJ, Burr DB, Delmas PD. Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int. 2008;19: 329-337.
3. Aspenberg P. Bisphosphonate-induced fractures: nature strikes back? Acta Orthop. 2008;79:459-160.
4. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-1541.
5. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long- term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927-2938.
6. Blaimont P, Halleux P, Jedwab J. [Distribution of bony restraints in the femur] [in French]. Rev Chir Orthop Reparatrice Appar Mot. 1968;54:303-319.
7. Butler JE, Brown SL, McConnell BG. Subtrochanteric stress fractures in runners. Am J Sports Med. 1982;10:228-232.
8. Currey JD. Effects of differences in mineralization on the mechanical properties of bone. Philos Trans R Soc Lond B Biol Sci. 1984;304:509-518.
9. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83: 1032-1045.
10. Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM; Fracture Intervention Trial Long-Term Extension Research Group. Randomized trial ofeffect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res. 2004;19:1259-1269.
11. Esterberg J, Kassim RA, Redmon J, Coad J, Macari GS, Saleh KJ. Hip pain in a case of hypophosphatemic osteomalacia. Am J Orthop. 2003;32:455-458.
12. Garbuio P, Pernin JN. The biomechanics of the hip and hip implants. Cahier d'enseignement de la SOFCOT. 1999;69:37-48.
13. Geusens P. Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment. Curr Osteoporos Rep. 2009;7:12-17.
14. Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89: 349-353.
15. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging attern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;39:224-231.
16. Leinberry CF, McShane RB, Stewart WG Jr, Hume EL. A displaced subtrochanteric stress fracture in a young amenorrheic athlete. Am J Sports Med. 1992;20:485-487.
17. Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009;20:1353-1362.
18. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001;28:524-531.
19. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22:346-350.
20. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005; 90:1294-1301.
21. Orcel P, de Vernejoul MC, Prier A, Miravet L, Kuntz D, Kaplan G. Stress fractures of the lower limbs in osteoporotic patients treated with fluoride. J Bone Miner Res. 1990;5(suppl 1):S191-S194.
22. Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab. 2005;90:1897-1899.
23. Pauwels F. Die Bedeutung der Bauprinzipien des Stutz- und Bewegungsapparates fur die Beanspruchung der Rohrenknochen; erster Beitrag zur funktionellen Anatomie und kausalen Mor- phologie des Stutzapparates. Z Anat Entwicklungsgesch. 1948; 114:129-166.
24. Sayed-Noor AS, Sjoden GO. Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy: a case report. Acta Orthop. 2008;79:565-567.
25. Sayed-Noor AS, Sjoden GO. Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res. 2009;467:1921-1926.
26. Schnitzler CM, Wing JR, Gear KA, Robson HJ. Bone fragility of the peripheral skeleton during fluoride therapy for osteoporosis. Clin Orthop Relat Res. 1990;261:268-275.
27. Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res. 2009;24:1736-1740.
28. Tosteson AN, Burge RT, Marshall DA, Lindsay R. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care. 2008;14:605-615.
29. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008;93:2948-2952.